

Endocyte Announces New Director of Clinical Operations

West Lafayette, Ind., Jan. 31, 2003 – Julie Engel, Ph.D., recently joined Endocyte, Inc. as the director of clinical operations.

“We are thrilled to have someone of Julie’s experience and skill in our organization,” said Ron Ellis, president and CEO of Endocyte, Inc., “She will play a critical role in managing the clinical trials for our exciting new products in the areas of oncology and arthritis.”

Prior to joining Endocyte, Dr. Engel spent 20 years in positions of increasing responsibility in both large pharmaceutical companies such as Eli Lilly and Company and small biotechnology companies like Applied Immune Sciences, Pharmacyclics, Inc, and ImClone Systems Inc. in the areas of infectious disease and oncology.

About Endocyte

Endocyte, Inc, headquartered in West Lafayette, Indiana, is developing a new generation of receptor-targeted therapeutics or smart drugs for the treatment of cancer and autoimmune diseases. Receptor-targeted therapeutics reduce side effects by targeting drugs to receptors present on diseased cells. For more information, please visit Endocyte's website at www.endocyte.com

###